CRISPR–Cas9 Delivery Strategies for the Modulation of Immune and Non-Immune Cells

Dr. Shahad Alsaiari recently published her article, "CRISPR–Cas9 Delivery Strategies for the Modulation of Immune and Non-Immune Cells," in Nature Reviews Materials, which explores the groundbreaking potential of CRISPR–Cas9 technology in reshaping immune responses. Her work underscores the advancements in ex vivo genome editing, while also addressing the hurdles of effective CRISPR–Cas9 component delivery to immune cells in vivo.

In this insightful review, Dr. Alsaiari not only outlines current delivery strategies for both immune and non-immune cells but also leverages findings from non-immune cell research to inspire future breakthroughs in immune therapies. The article navigates the principles and challenges of employing CRISPR–Cas9 for immune modulation, providing a strategic roadmap to tackle the obstacles that currently impede the therapeutic use of genome editing. 

Dr. Alsaiari’s research was completed during her postdoc work in MIT’s Langer Lab. Recently, Dr. Alsaiari joined the King Faisal Specialist Hospital and Research Center as an Associate Scientist in the Department of Bioengineering and Nanomedicine.

You can read the full article published October 2024 in Nature.